Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05808673
Other study ID # CMAB807X-001
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date February 2023
Est. completion date July 2024

Study information

Verified date February 2023
Source Taizhou Mabtech Pharmaceutical Co.,Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blinded, controlled Phase I three-arms study of CMAB807X administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807X Pre- and Post-change in Manufacturing Site, and Post-change CMAB807X versus Xgeva® #Denosumab# in healthy male subjects after a single dose


Description:

This is a randomized, double-blind, parallel-controlled, single-dose phase I three-arms clinical study in healthy Chinese male subjects. A total of 252 subjects were planned to be enrolled and randomly assigned to the test group or the bridging control group or bioequivalence control group in a 1:1:1 ratio. Subjects in three groups received a single abdominal subcutaneous injection of pre- or post-change CMAB807X or Xgeva® #Denosumab# 120 mg, respectively. Subjects in three groups were observed for 140 days after administration to evaluate similarities in pharmacokinetics, pharmacodynamics, safety, and immunogenicity.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. Healthy male volunteers, age ranged 18 to 45 years (both inclusive) when sign the informed consent form. 2. Subjects with body weight of =58 kg and = 68 kg and BMI =18 and = 28 kg/m2. 3. Subjects were willing to take effective contraceptive measures throughout the study period (including: physical contraception, surgery, abstinence, etc.,) until at least 6 months after administration. 4. Subjects have the ability to understand the full characteristics and objectives of the study, including the possible risks and side effects of the study; moreover, subjects can communicate well with researchers and complete the research according to the regulations. 5. Subjects must be informed consent of the study and voluntarily sign ICF (name and time) prior to the study. Exclusion Criteria: 1. After medical examination (vital signs, physical examination, electrocardiogram, chest X-radiography, cervical and abdominal B-ultrasound, and various laboratory examinations including blood routine, urine routine, blood biochemistry, etc.), any examination item was judged abnormal by the investigator and had clinical significance. 2. Serum calcium level were out of the normal range. 3. QTcF > 450 ms (12-lead ECG). 4. Inflammation or abnormalities in or around the site of administration. 5. Those who have a history of serious diseases including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, urinary system, digestive system, respiratory system, metabolic and skeletal systems, or currently have any of the above diseases or active infected diseases, or any other disease or medical condition that may interfere with the results of the trial, such as hereditary bleeding tendency, coagulation disorders or history of blood clots or bleeding. 6. Previous diagnosis of bone disorders that the investigator has determined to be clinically significant, or any disease that affects bone metabolism, including but not limited to: malignant tumors (including myeloma), hypothyroidism/hyperthyroidism, hypoparathyroidism/hyperthyroidism, acromegaly, Cushing's syndrome, hypopituitarism, severe chronic obstructive pulmonary disease, rheumatoid arthritis, osteomalacia, etc. 7. Subjects with past or current osteomyelitis or osteonecrosis of the jaw (ONJ), or risk factors for ONJ, such as dental disease or jaw disease requiring oral surgery, dental surgery; or plan to have dental surgery during the study. 8. Fracture occurred within 6 months prior to signing ICF. 9. Surgery within 6 months prior to signing ICF, or plan to have surgery during the study period. 10. Allergic to two or more drugs or foods, or to any component of the investigational agent. 11. Use of any prescription drug, over-the-counter drug, vitamin or herbal medicine within 30 days prior to signing ICF, or prior use of drugs within 5 half-lives, whichever is longer. 12. Use of any medications that have the potential to affect bone metabolism prior to administration (e.g., bisphosphonate or fluoride, estrogen, selective estrogen receptor modulators, calcitonin, parathyroid hormone, high-dose vitamin D (> 1000 IU/ day), anabolic steroids, systemic glucocorticoids, or percalcitriol within 6 months) 13. Use of anti-RANKL mab within 12 months, or any biological agent within 3 months prior to signing ICF. 14. Those who have received vaccine within the 4 weeks prior to signing ICF, or who plan to receive live vaccine during the study period. 15. History of drug abuse, or positive urine drug screening. 16. Those who had donated or lost blood at least 200 mL in the 3 months prior to signing ICF, or planned to donate blood during the study. 17. Those who can not tolerate venipunction, has a history of dizziness of needle and blood. 18. Those who have been enrolled in other drug or device clinical studies within 3 months prior to signing ICF. 19. Those who smoked more than 5 cigarettes per day in the 6 months prior to signing ICF and did not cooperate with smoking bans during the study period. 20. Those who consumed more than 14 units of alcohol per week (1 unit = 17.7mL ethanol, i.e., 1 unit = 357mL 5% beer or 43mL 40% liquor or 147mL 12% wine) in the 3 months prior to signing ICF, or not willing to ban alcohol during the study period. 21. Those who excessively daily consumed tea, coffee or caffeinated beverages (more than 8 cups, 1 cup =250mL) in the 3 months prior to signing ICF. 22. Those who have special dietary requirements, or can not accept uniform diet 23. Other conditions considered inappropriate to be included in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Post-change CMAB807X
for subcutaneous injection only
Pre-change CMAB807X
for subcutaneous injection only
Xgeva®
for subcutaneous injection only

Locations

Country Name City State
China The Second Hospital of Anhui Medical University Hefei Anhui

Sponsors (1)

Lead Sponsor Collaborator
Taizhou Mabtech Pharmaceutical Co.,Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage and Severity of Participants with Adverse Events Total Frequency and Severity of Adverse Events/Serious Adverse Events Within the Whole Time of the Study up to 3336 hours
Primary Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single injection of Denosumab up to 3336 hours
Primary Maximum Concentration of Denosumab Maximum Concentration of Denosumab After the Single Injection of denosumab up to 3336 hours
Secondary Time to Maximum Concentration of Denosumab Time to Maximum Concentration of Denosumab after the Single Injection of up to 3336 hours
Secondary Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3336 Hours Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3336 Hours After the Single Injection of Denosumab up to 3336 hours
Secondary Half time Half-time after the Single Injection of Denosumab up to 3336 hours
Secondary Clearance Rate Clearance Rate after the Single Injection of Denosumab up to 3336 hours
Secondary Apparent Volume of Distribution Apparent Volume of Distribution after the Single Injection of Denosumab up to 3336 hours
Secondary Serum type 1 C-telopeptide (CTX1) CTX1 level in the serum samples from subjects up to 3336 hours
Secondary anti-drug antibodies(ADA) ADA Positive Rate after the Single Injection of Denosumab up to 3336 hours
Secondary Neutralization antibodies(Nab) Neutralizing Antibody Positive Rate after the Single Injection of Denosumab up to 3336 hours
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1